ERs Genomics and Aelian Biotechnology announce CRISPR/Cas9 license agreement enabling Aelian's unique screening platform
DUBLIN, Ireland, and VIENNA, Austria, 11 February 2020: ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, and Aelian Biotechnology (“Aelian”) today announced the signing of a license agreement granting Aelian access to ERS Genomics' CRISPR/Cas9 patent portfolio, to support Aelian's commercial functional genomic screening platform.
Aelian Biotechnology combines CRISPR/Cas9 screening techniques with single-cell sequencing to identify and investigate disease targets and drug mechanisms of action. Aelian’s novel platform is applicable across a wide range of cell types, including primary cells, and broadens access to a wider range of complex phentoypes. Under the terms of the license from ERS Genomics, Aelian is now able to offer its technology worldwide to pharmaceutical and biotech companies seeking more effective therapies.
“Aelian is a very exciting group focused on an interesting and unique application of CRISPR/Cas9 technology,“ stated Eric Rhodes, CEO of ERS Genomics. “The Company’s screening platform has the ability to precisely identify the role of key genes in a wide variety of cell types, which is a transformative approach in this field. We look forward to watching Aelian's progress as they continue to push the boundaries of the technology."
“As a group that understands the power of CRISPR/Cas9 technology to enable cutting-edge research and discovery we are pleased to be able to secure this important license," stated Thomas Moser, CEO of Aelian Biotechnology. "We recognize the fundamental nature of the Charpentier patents and appreciate having the ability to gain access to them through ERS Genomics."
Financial details of the agreement are not disclosed
About ERS Genomics www.ersgenomics.com ERS Genomics is a biotechnology company based in Dublin, Ireland. The company was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property held by Dr. Emmanuelle Charpentier. Non-exclusive licenses are available for research and sale of products and services across multiple fields including: research tools, kits, reagents; discovery of novel targets for therapeutic intervention; cell lines for discovery and screening of novel drug candidates; GMP production of healthcare products; companion animal and livestock health; production of industrial materials such as enzymes, biofuels and chemicals; and synthetic biology. For additional information please visit www.ersgenomics.com.
About Aelian Biotechnology www.aelianbio.com Aelian Biotechnology combines CRISPR screening with single-cell sequencing, leveraging two transformative technologies to enable genetic screening for complex phenotypes. We utilize the CRISPR screening workflow to map the impact of thousands of genetic perturbations on the global transcriptome at single-cell resolution, thus effectively establishing a paradigm for next generation CRISPR screens. Our powerful approach has broad applications in identifying novel drug targets or elucidating unknown mechanisms of actions of drugs.